255 related articles for article (PubMed ID: 27320920)
1. In Vivo Functional Platform Targeting Patient-Derived Xenografts Identifies WDR5-Myc Association as a Critical Determinant of Pancreatic Cancer.
Carugo A; Genovese G; Seth S; Nezi L; Rose JL; Bossi D; Cicalese A; Shah PK; Viale A; Pettazzoni PF; Akdemir KC; Bristow CA; Robinson FS; Tepper J; Sanchez N; Gupta S; Estecio MR; Giuliani V; Dellino GI; Riva L; Yao W; Di Francesco ME; Green T; D'Alesio C; Corti D; Kang Y; Jones P; Wang H; Fleming JB; Maitra A; Pelicci PG; Chin L; DePinho RA; Lanfrancone L; Heffernan TP; Draetta GF
Cell Rep; 2016 Jun; 16(1):133-147. PubMed ID: 27320920
[TBL] [Abstract][Full Text] [Related]
2. Screening of Conditionally Reprogrammed Patient-Derived Carcinoma Cells Identifies ERCC3-MYC Interactions as a Target in Pancreatic Cancer.
Beglyarova N; Banina E; Zhou Y; Mukhamadeeva R; Andrianov G; Bobrov E; Lysenko E; Skobeleva N; Gabitova L; Restifo D; Pressman M; Serebriiskii IG; Hoffman JP; Paz K; Behrens D; Khazak V; Jablonski SA; Golemis EA; Weiner LM; Astsaturov I
Clin Cancer Res; 2016 Dec; 22(24):6153-6163. PubMed ID: 27384421
[TBL] [Abstract][Full Text] [Related]
3. β2-adrenergic receptor signaling promotes pancreatic ductal adenocarcinoma (PDAC) progression through facilitating PCBP2-dependent c-myc expression.
Wan C; Gong C; Zhang H; Hua L; Li X; Chen X; Chen Y; Ding X; He S; Cao W; Wang Y; Fan S; Xiao Y; Zhou G; Shen A
Cancer Lett; 2016 Apr; 373(1):67-76. PubMed ID: 26803058
[TBL] [Abstract][Full Text] [Related]
4. Regulation of GLI Underlies a Role for BET Bromodomains in Pancreatic Cancer Growth and the Tumor Microenvironment.
Huang Y; Nahar S; Nakagawa A; Fernandez-Barrena MG; Mertz JA; Bryant BM; Adams CE; Mino-Kenudson M; Von Alt KN; Chang K; Conery AR; Hatton C; Sims RJ; Fernandez-Zapico ME; Wang X; Lillemoe KD; Fernández-Del Castillo C; Warshaw AL; Thayer SP; Liss AS
Clin Cancer Res; 2016 Aug; 22(16):4259-70. PubMed ID: 27169995
[TBL] [Abstract][Full Text] [Related]
5. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
6. WDR5 Supports an N-Myc Transcriptional Complex That Drives a Protumorigenic Gene Expression Signature in Neuroblastoma.
Sun Y; Bell JL; Carter D; Gherardi S; Poulos RC; Milazzo G; Wong JW; Al-Awar R; Tee AE; Liu PY; Liu B; Atmadibrata B; Wong M; Trahair T; Zhao Q; Shohet JM; Haupt Y; Schulte JH; Brown PJ; Arrowsmith CH; Vedadi M; MacKenzie KL; Hüttelmaier S; Perini G; Marshall GM; Braithwaite A; Liu T
Cancer Res; 2015 Dec; 75(23):5143-54. PubMed ID: 26471359
[TBL] [Abstract][Full Text] [Related]
7. Ectopic HOTTIP expression induces noncanonical transactivation pathways to promote growth and invasiveness in pancreatic ductal adenocarcinoma.
Wong CH; Li CH; He Q; Chan SL; Tong JH; To KF; Lin LZ; Chen Y
Cancer Lett; 2020 May; 477():1-9. PubMed ID: 32120024
[TBL] [Abstract][Full Text] [Related]
8. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC.
Lankes K; Hassan Z; Doffo MJ; Schneeweis C; Lier S; Öllinger R; Rad R; Krämer OH; Keller U; Saur D; Reichert M; Schneider G; Wirth M
Mol Oncol; 2020 Dec; 14(12):3048-3064. PubMed ID: 33099868
[TBL] [Abstract][Full Text] [Related]
9. LINC00346 promotes pancreatic cancer progression through the CTCF-mediated Myc transcription.
Peng WX; He RZ; Zhang Z; Yang L; Mo YY
Oncogene; 2019 Oct; 38(41):6770-6780. PubMed ID: 31391552
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of PD2 leads to increased tumorigenicity and metastasis in pancreatic ductal adenocarcinoma.
Vaz AP; Deb S; Rachagani S; Dey P; Muniyan S; Lakshmanan I; Karmakar S; Smith L; Johansson S; Lele S; Ouellette M; Ponnusamy MP; Batra SK
Oncotarget; 2016 Jan; 7(3):3317-31. PubMed ID: 26689992
[TBL] [Abstract][Full Text] [Related]
11. A human cancer xenograft model utilizing normal pancreatic duct epithelial cells conditionally transformed with defined oncogenes.
Inagawa Y; Yamada K; Yugawa T; Ohno S; Hiraoka N; Esaki M; Shibata T; Aoki K; Saya H; Kiyono T
Carcinogenesis; 2014 Aug; 35(8):1840-6. PubMed ID: 24858378
[TBL] [Abstract][Full Text] [Related]
12. PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.
Giuliani V; Miller MA; Liu CY; Hartono SR; Class CA; Bristow CA; Suzuki E; Sanz LA; Gao G; Gay JP; Feng N; Rose JL; Tomihara H; Daniele JR; Peoples MD; Bardenhagen JP; Geck Do MK; Chang QE; Vangamudi B; Vellano C; Ying H; Deem AK; Do KA; Genovese G; Marszalek JR; Kovacs JJ; Kim M; Fleming JB; Guccione E; Viale A; Maitra A; Emilia Di Francesco M; Yap TA; Jones P; Draetta G; Carugo A; Chedin F; Heffernan TP
Nat Commun; 2021 Jul; 12(1):4626. PubMed ID: 34330913
[TBL] [Abstract][Full Text] [Related]
13. Involvement of CD40 targeting miR-224 and miR-486 on the progression of pancreatic ductal adenocarcinomas.
Mees ST; Mardin WA; Sielker S; Willscher E; Senninger N; Schleicher C; Colombo-Benkmann M; Haier J
Ann Surg Oncol; 2009 Aug; 16(8):2339-50. PubMed ID: 19475450
[TBL] [Abstract][Full Text] [Related]
14. WDR5 supports colon cancer cells by promoting methylation of H3K4 and suppressing DNA damage.
Neilsen BK; Chakraborty B; McCall JL; Frodyma DE; Sleightholm RL; Fisher KW; Lewis RE
BMC Cancer; 2018 Jun; 18(1):673. PubMed ID: 29925347
[TBL] [Abstract][Full Text] [Related]
15. Discovery of a potent MLL1 and WDR5 protein-protein interaction inhibitor with in vivo antitumor activity.
Chen W; Chen X; Li D; Wang X; Long G; Jiang Z; You Q; Guo X
Eur J Med Chem; 2021 Nov; 223():113677. PubMed ID: 34225179
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.
Mody HR; Hung SW; AlSaggar M; Griffin J; Govindarajan R
Mol Cancer Res; 2016 Nov; 14(11):1124-1135. PubMed ID: 27624777
[TBL] [Abstract][Full Text] [Related]
17. FBP1 loss contributes to BET inhibitors resistance by undermining c-Myc expression in pancreatic ductal adenocarcinoma.
Wang B; Fan P; Zhao J; Wu H; Jin X; Wu H
J Exp Clin Cancer Res; 2018 Sep; 37(1):224. PubMed ID: 30201002
[TBL] [Abstract][Full Text] [Related]
18. In Vivo RNAi Screening for Pancreatic Cancer Drivers: PILOTing the WDR5-MYC Axis.
Schneider G; Saur D
Trends Cancer; 2016 Aug; 2(8):391-392. PubMed ID: 28741490
[TBL] [Abstract][Full Text] [Related]
19. Stromal remodeling by the BET bromodomain inhibitor JQ1 suppresses the progression of human pancreatic cancer.
Yamamoto K; Tateishi K; Kudo Y; Hoshikawa M; Tanaka M; Nakatsuka T; Fujiwara H; Miyabayashi K; Takahashi R; Tanaka Y; Ijichi H; Nakai Y; Isayama H; Morishita Y; Aoki T; Sakamoto Y; Hasegawa K; Kokudo N; Fukayama M; Koike K
Oncotarget; 2016 Sep; 7(38):61469-61484. PubMed ID: 27528027
[TBL] [Abstract][Full Text] [Related]
20. Involvement of the tubulin tyrosine ligase-like family member 4 polyglutamylase in PELP1 polyglutamylation and chromatin remodeling in pancreatic cancer cells.
Kashiwaya K; Nakagawa H; Hosokawa M; Mochizuki Y; Ueda K; Piao L; Chung S; Hamamoto R; Eguchi H; Ohigashi H; Ishikawa O; Janke C; Shinomura Y; Nakamura Y
Cancer Res; 2010 May; 70(10):4024-33. PubMed ID: 20442285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]